Accolade (NASDAQ: ACCD) reported Q4 revenue for the quarter came in at $59.2 million versus the consensus estimate of $56.57 million.

“This has been a transformative year for Accolade. Our fiscal year began as Covid-19 was shutting down businesses and schools, forcing us to pivot quickly to respond to our own employees’ needs while continuing to play an even more important role in our members’ and customers’ healthcare. I am proud of the entire Accolade team and their steadfast focus and commitment to growing our portfolio, extending our relationships across the healthcare ecosystem, outperforming our financial targets, and delivering on our promises to our customers. Looking ahead, our acquisition of 2nd.MD and pending acquisition of PlushCare dramatically expand our addressable market opportunities, while also helping to introduce new conversations with customers who are looking for solutions that drive better outcomes for their employees while lowering their healthcare costs. Our proven track record of delivering these results has been the foundation of our success. We remain focused on reinventing healthcare, with a commitment to deliver a single solution that simplifies the care journey and empowers people to make the best decisions for their health and well-being,” said Rajeev Singh, Accolade CEO.

GUIDANCE:

Accolade sees Q1 2022 revenue of $54-56 million, versus the consensus of $53.43 million.

Accolade sees FY2022 revenue of $260-265 million, versus the consensus of $167.76 million.

For earnings history and earnings-related data on Accolade (ACCD) click here.